---
title: The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic
  value for treatment-free remission in chronic myeloid leukemia patients treated
  with imatinib
date: '2023-12-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38129513/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1byXLWG-5Hn0_qdLgZYpDfLA2UWGhGNgZGereuo1rJN2aoAQXP&fc=20220814223158&ff=20231222170703&v=2.18.0
source: (deep learning) AND ((leukemia) OR (lymphoma))
description: Membrane transporters are important determinants of drug bioavailability.
  Their expression and activity affect the intracellular drug concentration in leukemic
  cells impacting response to therapy. Pharmacogenomics represents genetic markers
  that reflect allele arrangement of genes encoding drug transporters associated with
  treatment response. In previous work, we identified SNP rs460089 located in the
  promotor of SLC22A4 gene encoding imatinib transporter OCTN1 as influential on response
  ...
disable_comments: true
---
Membrane transporters are important determinants of drug bioavailability. Their expression and activity affect the intracellular drug concentration in leukemic cells impacting response to therapy. Pharmacogenomics represents genetic markers that reflect allele arrangement of genes encoding drug transporters associated with treatment response. In previous work, we identified SNP rs460089 located in the promotor of SLC22A4 gene encoding imatinib transporter OCTN1 as influential on response ...